TMED7-TICAM2

Across TCGA pan-cancer cohorts, TMED7-TICAM2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of TMED7-TICAM2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TMED7-TICAM2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TMED7-TICAM2 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

HNSC, KIRC, and THCA are the cancer types where TMED7-TICAM2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMED7-TICAM2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	III,IV	+0.541	<.001	12	view →
KIRC	All	IV	+0.246	<.001	9	view →
THCA	All	II,III,IV	−0.139	<.001	9	view →
LUAD	Male	II,III,IV	+0.388	<.001	8	view →
LIHC	Male	All	+0.163	<.001	8	view →
COAD	Male	IV	+0.146	.001	7	view →
KIRP	All	II,III,IV	+0.233	.001	6	view →
BRCA	All	III,IV	+0.185	<.001	6	view →
LUSC	Male	II,III,IV	+0.258	<.001	4	view →
STAD	All	All	+0.141	.007	4	view →
ESCA	All	II,III,IV	+0.375	.014	3	view →
CHOL	All	All	+0.181	.023	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

TMED7-TICAM2–HNSC

Open the HNSC breakdown →